0.9223
Marker Therapeutics Inc stock is traded at $0.9223, with a volume of 118.77K.
It is up +3.61% in the last 24 hours and down -21.17% over the past month.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
See More
Previous Close:
$0.8902
Open:
$0.9571
24h Volume:
118.77K
Relative Volume:
1.24
Market Cap:
$15.38M
Revenue:
$3.20M
Net Income/Loss:
$-10.90M
P/E Ratio:
-1.3688
EPS:
-0.6738
Net Cash Flow:
$-7.92M
1W Performance:
-2.92%
1M Performance:
-21.17%
6M Performance:
-41.63%
1Y Performance:
-12.16%
Marker Therapeutics Inc Stock (MRKR) Company Profile
Name
Marker Therapeutics Inc
Sector
Industry
Phone
(713) 400-6400
Address
2450 HOLCOMBE BLVD, HOUSTON, TX
Compare MRKR vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
MRKR
Marker Therapeutics Inc
|
0.9223 | 15.38M | 3.20M | -10.90M | -7.92M | -0.6738 |
|
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Canaccord Genuity | Buy |
| Mar-25-21 | Initiated | Piper Sandler | Overweight |
| Mar-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-12-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| Mar-01-19 | Initiated | Janney | Buy |
| Dec-03-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Marker Therapeutics Inc Stock (MRKR) Latest News
Cerenome (Nasdaq:CNSY)Análisis de acciones - Simply Wall Street
Marker Therapeutics, Inc. Highlights Expanded Manufacturing Capabilities Supporting Mt-601 - marketscreener.com
Electra Therapeutics (ETRA) pursues IPO as auditor raises going-concern warning - Stock Titan
CAR T-cell Therapy for NHL Clinical Trial Landscape Expands: Over 70 Companies Advancing Next-Generation Therapies | DelveInsight - Business Upturn
CAR T-cell Therapy for NHL Clinical Trial Landscape Expands: Over 70 Companies Advancing Next-Generation Therapies | DelveInsight - The Manila Times
Marker Therapeutics (MRKR) Holds at $1.24 as Shares Trade Flat Within RangeIV Rank - dars.gov.et
Marker Therapeutics (MRKR) Holds at $1.24 as Shares Trade Flat Within RangeVolume Spike Alerts - siam.in
Marker Therapeutics (MRKR) Holds at $1.24 as Shares Trade Flat Within RangeUndervalued Stocks - dars.gov.et
Marker Therapeutics Inc. (MRKR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans? - webull.com
Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans? - Simply Wall Street
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com - Investing.com UK
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy - Investing.com
US High Growth Tech Stocks To Watch In August 2026 - simplywall.st
US High Growth Tech Stocks To Watch In August 2026 - simplywall.st
Marker Therapeutics (MRKR) Rises 1.75%, Holding Above Key $1.10 SupportIchimoku Kumo Twist - vinanet.vn
Marker Therapeutics (MRKR) Rises 1.75%, Holding Above Key $1.10 SupportHidden Order - careplusvn.com
Marker Therapeutics (MRKR) Rises 1.75%, Holding Above Key $1.10 SupportPrice Target - dars.gov.et
Marker Therapeutics (MRKR) Rises 1.75%, Holding Above Key $1.10 SupportRTH Profile - dars.gov.et
Marker Therapeutics Stock Price Forecast. Should You Buy MRKR? - StockInvest.us
Marker Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
MRKR Advances 2.7% to $1.14 as Biotech Stock Holds Above Key SupportVanna Flow - vinanet.vn
Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
MRKR Advances 2.7% to $1.14 as Biotech Stock Holds Above Key SupportSmart Money Flow Stocks - careplusvn.com
CCORF Maintains Marker Therapeutics(MRKR.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Stock List: Research Stocks from Around the World - GuruFocus
Marker Therapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Marker Therapeutics Inc (MRKR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MRKR Q1 2026 Earnings: Narrower-Than-Expected Loss of $0.16 Per Share Marks 14.44% EPS SurpriseAnnual Financial Report - careplusvn.com
MRKR Q1 2026 Earnings: Narrower-Than-Expected Loss of $0.16 Per Share Marks 14.44% EPS SurpriseProfit Inflection Point - vinanet.vn
MRKR Q1 2026 Earnings: Narrower-Than-Expected Loss of $0.16 Per Share Marks 14.44% EPS SurprisePeak Earnings Alert - dars.gov.et
MRKR Q1 2026 Earnings: Narrower-Than-Expected Loss of $0.16 Per Share Marks 14.44% EPS SurpriseBasic EPS Analysis - dars.gov.et
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Intellia Therapeutics
Cerenome (Nasdaq:CNSY)Aktienanalyse - Simply Wall Street
MRKR Q1 2026 Earnings: Narrower Loss Beats Estimates as Investors Focus on Clinical MilestonesGuidance Downgrade Alert - vinanet.vn
Marker Therapeutics, Inc. Revenue Breakdown – NASDAQ:MRKR - TradingView
Marker Therapeutics Inc (MRKR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Marker Therapeutics Inc (MRKR) Balance Sheet - TradingKey
Marker Therapeutics Inc (MRKR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Marker Therapeutics Inc (MRKR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Marker Therapeutics Inc (MRKR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
MRKR|Marker Therapeutics Inc|Price:1.200|Chg%:-0.020 - TradingKey
MRKR|Marker Therapeutics Inc|Price:1.220|Chg%:-0.050 - TradingKey
MRKR|Marker Therapeutics Inc|Price:1.200|Chg%:-0.020 - TradingKey
Marker Therapeutics Inc (MRKR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
US High Growth Tech Stocks to Watch for Potential Expansion - simplywall.st
Marker Therapeutics Inc Stock (MRKR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):